about
Bovine adenovirus type 3 virions cannot be rescued in vivo after full-length viral genome transfection in the absence of detectable polypeptide IX.Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley fever vaccine in mice.The relative magnitude of transgene-specific adaptive immune responses induced by human and chimpanzee adenovirus vectors differs between laboratory animals and a target species.Immune responses induced by replication-defective adenovirus expressing the C-terminal portion of the Mycoplasma hyopneumoniae P97 adhesin.Maternal immunization with chimpanzee adenovirus expressing RSV fusion protein protects against neonatal RSV pulmonary infection.Immunogenic and protective properties of GP5 and M structural proteins of porcine reproductive and respiratory syndrome virus expressed from replicating but nondisseminating adenovectors.S1 domain of the porcine epidemic diarrhea virus spike protein as a vaccine antigenPotency of a thermostabilised chimpanzee adenovirus Rift Valley Fever vaccine in cattle.Immunomodulation using genetically engineered bacteria for type III-mediated delivery of heterologous antigens and cytokines: potential application in vaccine and therapeutical developments.Salmonella vaccines in poultry: past, present and future.Future Prospects for the Development of Cost-Effective Adenovirus Vaccines.In vitro and in vivo studies of adenovirus-mediated human norepinephrine transporter gene transduction to hepatocellular carcinoma.Exploration of New Sites in Adenovirus Hexon for Foreign Peptides Insertion.Biosafety evaluation of recombinant protein production in goat mammary gland using adenoviral vectors: preliminary study.Vaccines as alternatives to antibiotics for food producing animals. Part 2: new approaches and potential solutions
P2860
Q33848987-2FAB752A-2D4D-4C66-A18B-56DDEAF70317Q34529382-D425FA9A-3335-45AC-82F6-920C465E0881Q35091556-13037441-54E9-4C24-9A54-CDE66071EEAEQ35946937-E4486195-33D5-4C1D-B6E3-C2C34B16ACB2Q36463070-2F17BFCE-B2F8-4D59-BF52-9358F492FFE5Q36715877-BF5BAC56-AF9D-41CA-8DAA-6D7CEB8AC3B7Q36758318-33EFAC8A-82C4-4801-9101-C307EEBC84F0Q36852321-3C2719C4-60A8-4ACC-A333-E819B0F2E20AQ37602699-4267109B-5E82-4219-9CF6-32941843D91EQ38068955-CBC88AD2-5311-4D18-AF2A-2562795BA34AQ38728732-059A6920-374F-4CDB-8E34-24FEFAC52F82Q39632795-C5FAFFA0-D8AF-4F88-A8CB-BF5A1971AA5DQ41165765-CF409A31-58BA-42ED-90EE-1BD9D4782B7DQ50250340-F9B36ED2-F2F8-4263-BAB1-681A29B1779DQ56892183-4805095A-D34F-4EF6-8551-D43B4CD2108A
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Use of adenoviral vectors as veterinary vaccines.
@ast
Use of adenoviral vectors as veterinary vaccines.
@en
type
label
Use of adenoviral vectors as veterinary vaccines.
@ast
Use of adenoviral vectors as veterinary vaccines.
@en
prefLabel
Use of adenoviral vectors as veterinary vaccines.
@ast
Use of adenoviral vectors as veterinary vaccines.
@en
P2093
P2860
P356
P1433
P1476
Use of adenoviral vectors as veterinary vaccines.
@en
P2093
Carrondo MJ
Ferreira TB
P2860
P2888
P304
P356
10.1038/SJ.GT.3302618
P478
12 Suppl 1
P577
2005-10-01T00:00:00Z